Erin Colgan
Treasurer at Massachusetts Biotechnology Education Foundation
Net worth: 70 835 $ as of 2024-03-30
Profile
Erin Colgan is currently the Treasurer at the Massachusetts Biotechnology Education Foundation.
Previously, Ms. Colgan held the position of Senior Director-Global Revenue at Vertex Pharmaceuticals, Inc. from 2010 to 2019.
Ms. Colgan then served as the Vice President-Commercial Planning at Intarcia Therapeutics, Inc. from 2019 to 2020.
Currently, Ms. Colgan is also the Chief Financial Officer at Sensei Biotherapeutics, Inc. starting from 2022.
Ms. Colgan obtained an undergraduate degree from the University of Massachusetts.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-14 | 67,462 ( 0.27% ) | 70 835 $ | 2024-03-30 |
Erin Colgan active positions
| Companies | Position | Start |
|---|---|---|
Massachusetts Biotechnology Education Foundation
 Massachusetts Biotechnology Education Foundation Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Education Foundation supports science and biotechnology education in Massachusetts through school programs and workforce training. The company was founded in 2001 and is headquartered in Cambridge, MA. | Treasurer | - |
Former positions of Erin Colgan
| Companies | Position | End |
|---|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 2024-04-09 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 2020-05-31 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 2019-07-31 |
Training of Erin Colgan
| University of Massachusetts | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Private companies | 3 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Massachusetts Biotechnology Education Foundation
Massachusetts Biotechnology Education Foundation Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Education Foundation supports science and biotechnology education in Massachusetts through school programs and workforce training. The company was founded in 2001 and is headquartered in Cambridge, MA. | Commercial Services |
| Sensei Biotherapeutics, Inc. |
- Stock Market
- Insiders
- Erin Colgan